{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:27:11Z","timestamp":1777901231866,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2026.103567","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:13:44Z","timestamp":1770884024000},"page":"103567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia"],"prefix":"10.1016","volume":"74","author":[{"given":"Misa","family":"Eugene Norbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Cuffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Blondel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Dehayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Giverne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystel","family":"Marton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica L.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Latouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-307X","authenticated-orcid":false,"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.retram.2026.103567_bib0001","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103567_bib0002","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013Modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.retram.2026.103567_bib0003","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013Modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"177","key":"10.1016\/j.retram.2026.103567_bib0004","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.retram.2026.103567_bib0005","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.retram.2026.103567_bib0006","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.retram.2026.103567_bib0007","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.retram.2026.103567_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood.V80.2.470.470","article-title":"Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34","volume":"80","author":"Kita","year":"1992","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2026.103567_bib0009","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103567_bib0010","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.4898-24","article-title":"Therapy-related trilineage mixed phenotype acute leukemia treated with venetoclax and azacitidine","author":"Yamamoto","year":"2025","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.retram.2026.103567_bib0011","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3390\/cancers17081354","article-title":"Association between B-cell marker expression and RUNX1 lesions in acute myeloid leukemia, beyond RUNX1::RUNX1T1 fusion: diagnostic pitfalls with mixed-phenotype acute leukemia\u2014B\/myeloid","volume":"17","author":"George","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.retram.2026.103567_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLOS ONE"},{"issue":"12","key":"10.1016\/j.retram.2026.103567_bib0013","first-page":"4131","article-title":"Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia","volume":"109","author":"Barneh","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103567_bib0014","first-page":"42","article-title":"Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia","volume":"9","author":"Ma","year":"2018","journal-title":"Leuk Res Rep"},{"issue":"5","key":"10.1016\/j.retram.2026.103567_bib0015","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2026.103567_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2023.113603","article-title":"Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells","volume":"525","author":"Eugene-Norbert","year":"2024","journal-title":"J Immunol Methods"},{"issue":"21","key":"10.1016\/j.retram.2026.103567_bib0017","doi-asserted-by":"crossref","first-page":"11400","DOI":"10.1073\/pnas.93.21.11400","article-title":"A stable human-derived packaging cell line for production of high titer retrovirus\/vesicular stomatitis virus G pseudotypes","volume":"93","author":"Ory","year":"1996","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.retram.2026.103567_bib0018","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"McCormack","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.retram.2026.103567_bib0019","first-page":"2618","article-title":"Update of humanized animal disease models in studying graft-versus-host disease","volume":"14","author":"Huang","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"6","key":"10.1016\/j.retram.2026.103567_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.015","article-title":"Simple, rapid, reproducible and biomarker-validated clinical grading system for murine models of xenogeneic graft-versus-host disease","volume":"31","author":"Thiolat","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.retram.2026.103567_bib0021","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s42003-024-06770-w","article-title":"CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder","volume":"7","author":"Folimonova","year":"2024","journal-title":"Commun Biol"},{"issue":"12","key":"10.1016\/j.retram.2026.103567_bib0022","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41590-023-01663-2","article-title":"CD3\u03b6 ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides","volume":"24","author":"Gaud","year":"2023","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.retram.2026.103567_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41419-023-05829-6","article-title":"Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia","volume":"14","author":"Sugita","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.retram.2026.103567_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141364","article-title":"Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: existing methods, challenges, clinical success, and future prospects : a comprehensive review","volume":"306","author":"Tulsian","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"10.1016\/j.retram.2026.103567_bib0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41409-018-0423-y","article-title":"Successful treatment of two relapsed\/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells","volume":"54","author":"Qu","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.retram.2026.103567_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"7","key":"10.1016\/j.retram.2026.103567_bib0027","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41375-020-0719-y","article-title":"Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells","volume":"34","author":"Danylesko","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.retram.2026.103567_bib0028","article-title":"Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression","volume":"72","author":"Danylesko","year":"2024","journal-title":"Curr Res Transl Med"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:55:47Z","timestamp":1777632947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452318626000048"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103567","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103567"}}